Patent · US Active

Use of SHROOM3 in chronic kidney disease and chronic allograft nephropathy

US11098361B2 · kind B2 · utility

0Cited by

0References

9Claims

0Family size

Assignee

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · US

Inventors

Barbara Murphy · Pelham Manor, US
John Cijiang He · New Taipei, TW

Key dates

Filing date	Mar 10, 2014
Grant date	Aug 24, 2021
Priority date	—
Expiry date	Mar 10, 2034

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/50
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method for identifying the risk of developing Chronic Allograft Nephropathy (CAN) in a patient that received a kidney transplant from a donor which comprises identifying the race of the donor; determining the levels of SHROOM 3 expression in a kidney biopsy specimen obtained from the patient at a predetermined time after transplant; comparing the level of SHROOM 3 expression in the biopsy specimen with the levels of SHROOM 3 expression in a control; determining if the level of SHROOM 3 expression in the allograft is significantly higher than in the control, and diagnosing the patient as being at risk for CAN if the level of SHROOM 3 expression in the specimen is significantly higher than in the control.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.